Skip to navigation Skip to content

Non-small cell lung cancer (NSCLC) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051128

Expand/Collapse all sectionsExpand all



This document outlines details of PBS-subsidised crizotinib, entrectinib and repotrectinib for patients with Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC).

For details on how to process a PBS Authority, see Processing Complex Authority Required Listings.

On this page:

Non-small cell lung cancer (NSCLC) - crizotinib quick reference

Non-small cell lung cancer (NSCLC) - entrectinib and repotrectinib quick reference

Non-small cell lung cancer (NSCLC) - crizotinib quick reference

Table 1

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

PB156 form

Written

Electronic

S85

crizotinib

No

OPA

Must be treated by a:

  • medical practitioner

Yes

Continuing

Telephone

Electronic

S85

crizotinib

No

OPA

Must be treated by a:

  • medical practitioner
  • nurse practitioner where patient care is being shared with a medical practitioner and the prescription continues existing therapy with this medicine

Yes


Non-small cell lung cancer (NSCLC) - entrectinib and repotrectinib quick reference

Table 2

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

PB156 form

Written

Electronic

S85

entrectinib

repotrectinib

No

OPA

Not specified

Yes

Continuing

Telephone

Electronic

S85

entrectinib

repotrectinib

No

OPA

Not specified

Yes